Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 171-176

  Sato, Akinori ^a   Ito, Keiichi ^a   Asano, Takako ^a   Sumitomo, Makoto ^a   Asano, Tomohiko ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Renal cancer; siRNA; Survivin; Topotecan; Transfection efficiency

Indexed keywords

SMALL INTERFERING RNA; SURVIVIN; TOPOTECAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 38749090862     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.171     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 49: 8-31, 1999.
2. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
3. Mulders P, Figlin R, De Kernion JB, Wiltrout R, Linehan M, Parkinson D, de Wolf W and Belldegrun A: Renal cell carcinoma: recent progress and future directions. Cancer Res 57: 5189-5195, 1997.
4. Pittman K and Selby P: The management of renal cell carcinoma. Crit Rev Oncol Hematol 16: 181-200, 1994.
5. Autenrieth M, Heidenreich A and Gschwend JE: Systemic therapy of metastatic renal cell carcinoma. Urologe A 45: 594-599, 2006.
6. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R and Pazdur R: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.
7. Altieri DC and Marchisio PC: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
8. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
9. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
10. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
11. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, Hayakawa M and Murai M: Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-l, intefferon-γ and a novel NF-κB inhibitor. Int J Oncol 28: 841-846, 2006.
12. Saro A, Ito K, Asano T, Sumitomo M, Asano T and Hayakawa M: Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. Int J Oncol 30: 695-700, 2007.
13. Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Wurl P, Blumke K, Schmidt H, Meye A and Taubert H: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 11: 186-193, 2004.
14. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
15. LaCasse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 323-327, 1998.
16. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y and Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107: 746-756, 2006.
17. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG and Zaffaroni N: Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5: 179-186, 2006.
18. Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
19. Li S and Huang L: Non-viral gene therapy: promises and challenges. Gene Ther 7: 31-34, 2000.
20. Fujimaki K, Aratani Y, Fujisawa S, Motomura S, Okubo T and Koyama H: DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes. Somat Cell Mol Genet 22: 279-290, 1996.
21. Koster F, Felberbaum R, Finas D, Wunsch K, Schulz C, Diedrich K and Hauser C: Progesterone and estradiol enhance lipid mediated transfection of Sk-Br-3 mammalian cancer cells. Int J Mol Med 9: 617-620, 2002.
22. Ohmiya N, Emi N, Niwa Y, Goto H and Hayakawa T: Insulin-enhanced liposome-mediated gene transfer into a gastric carcinoma cell line. Clin Exp Pharmacol Physiol 29: 544-548, 2002.
23. Eckardt JR: Emerging role of weekly topotecan in recurrent small cell lung cancer: Oncologist 9 (Suppl 6): 25-32, 2004.
24. McGuire WP, Blessing JA, Bookman MA, Lentz SS and Dunton CJ: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 18: 1062-1067, 2000.
25. Moore DH: Chemotherapy for recurrent cervical carcinoma. Curr Opin Oncol 18: 516-519, 2006.
26. Law TM, Ilson DH and Motzer RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12: 143-145, 1994.
27. Griffith TS and Kemp TJ: The topoisomerase I inhibitor topotezcan increases the sensitivity of prostate tumor cells to TRAIL/ Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 52: 175-184, 2003.
28. Mialon A, Sankinen M, Soderstrom H, Junttila TT, Holmstrom T, Koivusalo R, Papageorgiou AC, Johnson RS, Hietanen S, Elenius K and Westermarck J: DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. Mol Cell Biol 25: 5040-5051, 2005.
29. Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B and Wan Y: Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27: 823-830, 2005.
30. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T and Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: (Review). Ann Oncol 17: 1185-1196, 2006.
31. Dass CR: Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 82: 579-591,2004.
32. Tamaddon AM, Shirazi FH and Moghimi HR: Modeling cytoplasmic release of encapsulated oligonucleotides from cationic liposomes. Int J Pharm 336: 174-182, 2007.
33. Oliveira S, van Rooy I, Kranenburg O, Storm G and Schiffelers RM: Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm 331: 211-214, 2007.